Arturo Molina MD - 09 Jun 2025 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Medical Officer
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD
Issuer symbol
PTGX
Transactions as of
09 Jun 2025
Net transactions value
-$964,600
Form type
4
Filing time
11 Jun 2025, 17:40:40 UTC
Previous filing
14 Mar 2025
Next filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MOLINA ARTURO MD Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK /s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD 11 Jun 2025 0001398940

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $80,400 +10,000 +12% $8.04 93,892 09 Jun 2025 Direct
transaction PTGX Common Stock Sale $555,100 -10,000 -11% $55.51 83,892 09 Jun 2025 Direct F1
transaction PTGX Common Stock Options Exercise $80,400 +10,000 +12% $8.04 93,892 10 Jun 2025 Direct
transaction PTGX Common Stock Sale $570,300 -10,000 -11% $57.03 83,892 10 Jun 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -10,000 -10% $0.000000 85,971 09 Jun 2025 Common Stock 10,000 $8.04 Direct F3
transaction PTGX Stock Option (right to buy) Options Exercise $0 -10,000 -12% $0.000000 75,971 10 Jun 2025 Common Stock 10,000 $8.04 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.18 to $55.75. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.665 to $57.48. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer.